Objective: To investigate the correlation between the level of serum adipokines Metrnl and the metabolism of glucose, lipid and liver function in type 2 diabetes mellitus (T2DM) patients with nonalcoholic fatty liver disease (NAFLD). Methods: A total of 160 study subjects who were hospitalized and underwent physical examinations in the geriatric department of the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology from January 2021 to December 2022 were selected. They were divided into a simple T2DM group (n=57 cases), a T2DM combined with NAFLD group (n=38 cases), and a control group (65 cases) based on whether they met the diagnostic criteria for NAFLD and T2DM. The anthropometric parameters were recorded, and fasting blood glucose (FBG), fasting insulin (FINS), glutamic transaminase (AST), glutamic transaminase (ALT), γ- Glutamyl transpeptidase (GGT), albumin, total cholesterol (TC), total cholesterol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glycosylated hemoglobin Ah (HbA1C), uric acid (UA), and fat factor Metrnl were compared between groups. The correlation between Metrnl, glucose and lipid metabolism, and liver function in patients with T2DM combined with NAFLD were observed. Results: The levels of Metrnl and albumin in the pure T2DM group were lower than those in the control group (P＜0.05), while the levels of FBG, TC, and HbA1c in the pure T2DM group were higher than those in the control group (P＜0.05); The levels of Metrnl and albumin in the T2DM combined with NAFLD group were lower than those in the control group (P＜0.05), while the levels of AST, ALT, GGT, TG, LDL-C, FBG, and HbA1c in the T2DM combined with NAFLD group were higher than those in the control group (P＜0.05); The Metrnl levels in the T2DM combined with NAFLD group were lower than those in the T2DM group, while the AST and GGT levels in the T2DM combined with NAFLD group were higher than those in the T2DM group (P＜0.05). Correlation analysis showed that Metrnl was negatively correlated with GGT (r=-0.288), FBG (r=-0.714), HbA1c (r=-0.513), and TG (r=-0.2) (P＜0.05). The results of multiple logistic analysis showed that Metrnl, FBG, LDL-C, and albumin were all independent influencing factors for the occurrence of T2DM combined with NAFLD (P＜0.05). Conclusion: The levels of Metrnl in NAFLD patients are lower than those in the control group, and there is a negative correlation between Metrnl levels and FBG, HbA1c, TG, GGT levels. The decrease in Metrnl levels is an independent risk factor for the occurrence of T2DM combined with NAFLD, suggesting that Metrnl is a protective factor that may improve glucose and lipid metabolism disorders in T2DM combined with NAFLD patients and provide new ideas for disease treatment.
HU Jiayu
,
SUN Tingting
,
YANG Wei
,
JIN Meina
,
ZHOU Xueli
,
WEI Cuiying
. Correlation between serum metrnl level and glucose, lipid metabolism and liver function in type 2 diabetes patients with nonalcoholic fatty liver disease[J]. Journal of Baotou Medical College, 2024
, 40(5)
: 17
-21
.
DOI: 10.16833/j.cnki.jbmc.2024.05.004
[1] Raza S. Current treatment paradigms and emerging therapies for NAFLD/NASH[J]. Front Biosci, 2021, 26(2): 206-237.
[2] Canfora EE, Meex RCR, Venema K, et al. Gut microbial metabolites in obesity, NAFLD and T2DM[J]. Nat Rev Endocrinol, 2019, 15(5): 261-273.
[3] Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)[J]. J Diabetes Res, 2020, 2020: 3920196.
[4] Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 599-612.
[5] Zheng SL, Li ZY, Song J, et al. Metrnl: a secreted protein with new emerging functions[J]. Acta Pharmacol Sin, 2016, 37(5): 571-579.
[6] 陆菊明. 《中国2型糖尿病防治指南(2020年版)》读后感[J]. 中华糖尿病杂志, 2021, 13(4): 301-304.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 167-170.
[8] Meroni M, Longo M, Rustichelli A, et al. Nutrition and genetics in NAFLD: the perfect binomium[J]. Int J Mol Sci, 2020, 21(8): 2986.
[9] Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts[J]. Curr Pharm Des, 2018, 24(38): 4574-4586.
[10] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.
[11] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease[J]. Gastroenterology, 2020, 158(7): 1851-1864.
[12] Younossi ZM, Golabi P, De Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
[13] Muzica CM, Sfarti C, Trifan A, et al. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship[J]. Can J Gastroenterol Hepatol, 2020, 2020: 6638306.
[14] Alizadeh H. Myokine-mediated exercise effects: the role of myokine meteorin-like hormone (Metrnl)[J]. Growth Factors, 2021, 39(1/2/3/4/5/6): 71-78.
[15] Zhou JH, Zhou F, Wang WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
[16] 王琪璋, 何韬, 张祥波, 等. 非肥胖型非酒精性脂肪性肝病临床特点分析[J]. 健康研究, 2021, 41(3): 311-315.
[17] Alizadeh H. Meteorin-like protein (Metrnl): a metabolic syndrome biomarker and an exercise mediator[J]. Cytokine, 2022, 157: 155952.
[18] Mir N, Chin SA, Riddell MC, et al. Genomic and non-genomic actions of glucocorticoids on adipose tissue lipid metabolism[J]. Int J Mol Sci, 2021, 22(16): 8503.
[19] Parlati L, Régnier M, Guillou H, et al. New targets for NAFLD[J]. JHEP Rep, 2021, 3(6): 100346.
